The effects of booster vaccination of hepatitis B vaccine on anti-HBV surface antigen negative children 11-15 years after primary vaccination.

Authors:
Address: Department of Immune Prevention, Zhejiang Center for Disease Control and Prevention, Hangzhou, China. jyao@CDC.zj.cn
Journal:


Publication:

abstract

The twin aims of this study were to investigate the changes in anti-HBs IgG levels after booster vaccinations and to compare the effects of different vaccine doses in children aged 11-15 years who were both negative for HBsAg and had an Anti-HBs < 10.0 mIU/mL after primary vaccination. Children who were born between 1993 and 1998 and who had completed their hepatitis B vaccination program in infancy were randomly recruited to the study. The participants were divided into three groups according to their anti-HBs IgG levels: group I had a level < 0.1 mIU/mL; group II 0.1 - < 1.0 mIU/mL, and group III 1.0 - < 10.0 mIU/mL. The booster vaccination program comprised three (20μg) doses of HepB (CHO) vaccine administered at zero, one and six months after they are join this program: anti-HBs levels were measured one month after the first and third vaccinations. Among 448 HBsAg-negative infants, anti-HBs seroconversion rates (defined as an anti-HBs >= 10 mIU/mL) after the first and third vaccinations were 85.5% and 98.6% respectively - these observed differences were statistically significant (χ2 [1dof] = 50.11, p< 0.05). Seroconversion rates and GMTs after the first and third doses were significantly lower for group I children than the other two groups (p< 0.05). Compared, the OR of being negative (anti-HBs< 10mIU/ml) in group I after the first and the third dose were 7.66 (95%CI: 4.35-13.47, P< 0.05) and 20.48 (95% CI: 2.36-177.67, P< 0.05). So the anti-HBs titer levels decay to 10mIU/ml in 11-15 years of age children completed HepB Basic immunization, which need for booster immunization. The effect is better for those children with a relatively higher antibody titer before booster, and the effect of three doses booster is best.



Related Articles
Hepatitis B immune memory in children primed with hexavalent vaccines and given monovalent booster vaccines: an open-label, randomised, controlled, multicentre study.
Lancet Infect Dis. 2010
Hepatitis B immune memory in children primed with hexavalent vaccines and given monovalent booster vaccines: an open-label, randomised, controlled, multicentre study.
Zanetti AR, Romanò L, Giambi C, Pavan A, Carnelli V, Baitelli G, Malchiodi G, Valerio E, Barale A, Marchisio MA, et al. Lancet Infect Dis. 2010 Nov; 10(11):755-61. Epub 2010 Sep 29.
Comparative long term immunogenicity of two recombinant hepatitis B vaccines and the effect of a booster dose given after five years in a low endemicity country.
Pediatr Infect Dis J. 2005
Comparative long term immunogenicity of two recombinant hepatitis B vaccines and the effect of a booster dose given after five years in a low endemicity country.
Duval B, Gîlca V, Boulianne N, De Wals P, Massé R, Trudeau G, De Serres G. Pediatr Infect Dis J. 2005 Mar; 24(3):213-8.
Hepatitis B immunity and response to booster vaccination in children with inflammatory bowel disease treated with infliximab.
Am J Gastroenterol. 2012
Hepatitis B immunity and response to booster vaccination in children with inflammatory bowel disease treated with infliximab.
Moses J, Alkhouri N, Shannon A, Raig K, Lopez R, Danziger-Isakov L, Feldstein AE, Zein NN, Wyllie R, Carter-Kent C. Am J Gastroenterol. 2012 Jan; 107(1):133-8. Epub 2011 Aug 30.
Presence of immune memory and immunity to hepatitis B virus in adults after neonatal hepatitis B vaccination.
Vaccine. 2011
Presence of immune memory and immunity to hepatitis B virus in adults after neonatal hepatitis B vaccination.
Zhu CL, Liu P, Chen T, Ni Z, Lu LL, Huang F, Lu J, Sun Z, Qu C. Vaccine. 2011 Oct 13; 29(44):7835-41. Epub 2011 Aug 2.
Long-term immunogenicity of hepatitis B vaccination and policy for booster: an Italian multicentre study.
Lancet. 2005
Long-term immunogenicity of hepatitis B vaccination and policy for booster: an Italian multicentre study.
Zanetti AR, Mariano A, Romanò L, D'Amelio R, Chironna M, Coppola RC, Cuccia M, Mangione R, Marrone F, Negrone FS, et al. Lancet. 2005 Oct 15-21; 366(9494):1379-84.

To top Home


Show map | Diseases | Vaccination | Chronic disease | Medicine | Pregnancy | Heat & Sunburn | Cold | Security | Useful tips | Faq | News

TraveldoctorOnline 2001 • Disclaimer webmaster

The contents within traveldoctoronline are presented only for informational purposes and cannot substitute for professional health care or any other medical treatment.All users of this website with health problems should be oblige always to consult their medical doctor before starting any treatment.